Meeting
2015 ASCO Annual Meeting
Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
Authors
Elliott F. Winton
Emory Univ School of Medcn, Atlanta, GA
Elliott F. Winton , Timothy Devos , Stephen T. Oh , Uwe Platzbecker , Martha Wadleigh , Susie Jun , Peter Lee , Wei Deng , Vikas Gupta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT01969838
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS7101)
DOI
10.1200/jco.2015.33.15_suppl.tps7101
Abstract #
TPS7101
Poster Bd #
86b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
First Author: Vikas Gupta
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang
Poster
2021 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.
First Author: Abdulraheem Yacoub
Poster
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark Andrew Dickson